AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36307826 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin, with genetic polymorphisms analysis for 15 SNPs.
Number of subjects: 180
Study 36307845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) 15 Gy/1 fraction after SBRT 40 Gy/5 fractions
Number of subjects: 0
Study 36308640 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 100 mg CBD:100 mg THC
Number of subjects: 39
Study 36309156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid VT/VF group (28 patients with rapid VT/VF episodes)
Number of subjects: 144
Study 36309156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid VT/VF group
Number of subjects: 144
Study 36309156 — intervention group
Group type: EXPERIMENTAL
Intervention: VT/VF episodes
Number of subjects: 144
Study 36309156 — intervention group
Group type: COMPARATOR
Intervention: First documented nonrapid VT episode
Number of subjects: 144
Study 36309347 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination with reported adverse events
Number of subjects: 1430
Study 36309347 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination with short-term VAEs
Number of subjects: 1430
Study 36309488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (IMT) at home, 80% of max, daily in Phase 1 and 2, once weekly in Phase 3, self-selected frequency in Phase 4, with one weekly supervised session except Phase 4
Number of subjects: 10
Study 36309488 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 10
Study 36309572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 402
Study 36309748 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-energy diet (VLED) for 12 months
Number of subjects: 246
Study 36309837 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat (300 mg) plus durvalumab
Number of subjects: 0
Study 36309981 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (100, 200, or 400 mg daily for 14 days every 28-day cycle) + Azacitidine (75 mg/m² on Days 1-7 every cycle)
Number of subjects: 0
Study 36310331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Number of subjects: 655
Study 36310395 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with unvaccinated ED patients regarding COVID-19 vaccination concerns and potential approaches to increase vaccine acceptance.
Number of subjects: 65
Study 36310395 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusted messengers identified during interviews.
Number of subjects: 65
Study 36310566 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) with feeding modifications
Number of subjects: 94
Study 36310566 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) alone
Number of subjects: 94
Study 36310566 — intervention group
Group type: EXPERIMENTAL
Intervention: I-GERQ-R
Number of subjects: 94
Study 36310566 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI therapy
Number of subjects: 94
Study 36311227 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 54
Study 36311227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 54
Study 36311227 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 36311929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction CT
Number of subjects: 190
Study 36311929 — intervention group
Group type: COMPARATOR
Intervention: Standard chest CT
Number of subjects: 190
Study 36313025 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based multidomain intervention (FMI) for 24 weeks
Number of subjects: 0
Study 36313025 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36313054 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment in the emergency department
Number of subjects: 0
Study 36313083 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD) with standard obstetrical and gynecological follow-up and nutritional counseling to promote MD
Number of subjects: 138
Study 36313083 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetrical and gynecological follow-up alone
Number of subjects: 138
Study 36313083 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 138
Study 36313089 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 62
Study 36313089 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 62
Study 36313089 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (SF)
Number of subjects: 62
Study 36313095 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre/low red and processed meat intake (HFLM)
Number of subjects: 233
Study 36313095 — intervention group
Group type: COMPARATOR
Intervention: Low fibre/high red and processed meat intake (LFHM)
Number of subjects: 233
Study 36313095 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre/low red and processed meat intake (HFLM) in RA patients
Number of subjects: 233
Study 36313145 — intervention group
Group type: EXPERIMENTAL
Intervention: Orelabrutinib 150 mg orally daily until disease progression or unacceptable toxicity
Number of subjects: 47
Study 36313720 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced abdominopelvic CT
Number of subjects: 20
Study 36313720 — intervention group
Group type: COMPARATOR
Intervention: PET
Number of subjects: 20
Study 36313720 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 20
Study 36314021 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical intervention (specific details not provided)
Number of subjects: 0
Study 36314033 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reflective decision assistance strategies based on reminders and decision support tools
Number of subjects: 0
Study 36314033 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision information strategies based on knowledge dissemination
Number of subjects: 0
Study 36314033 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective decision-making restructuring strategies (audit and feedback with intention formation interventions)
Number of subjects: 0
Study 36314106 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Converting Enzyme 2 expressed in lettuce chloroplasts
Number of subjects: 0
Study 36314131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue cases with emotional distress (moderate-to-severe distress)
Number of subjects: 1023
Study 36314131 — intervention group
Group type: COMPARATOR
Intervention: Fatigue cases without emotional distress
Number of subjects: 1023
Study 36314131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue cases differentiated by obesity
Number of subjects: 1023
Study 36314131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue cases differentiated by pain
Number of subjects: 1023
Study 36314131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue cases without emotional distress, obesity, or pain
Number of subjects: 1023
Study 36314160 — intervention group
Group type: EXPERIMENTAL
Intervention: POC whole-blood hs-cTnI assay (Atellica VTLi) with a threshold of <4 ng/L
Number of subjects: 2572
Study 36314160 — intervention group
Group type: EXPERIMENTAL
Intervention: POC whole-blood hs-cTnI assay (Atellica VTLi)
Number of subjects: 2572
Study 36314198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis inhalation
Number of subjects: 0
Study 36314507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 66
Study 36314507 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management (Control)
Number of subjects: 66
Study 36314999 — intervention group
Group type: EXPERIMENTAL
Intervention: First Booster of SARS-COV-2 mRNA Vaccine
Number of subjects: 0
Study 36315007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat with azacitidine
Number of subjects: 0
Study 36315007 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36315182 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with hospitals
Number of subjects: 0
Study 36315224 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS text message reminders to follow their chosen anchoring plan (messages group; treatment group 1)
Number of subjects: 150
Study 36315224 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS text messages and incentives conditional on taking their ART medication around the time of their chosen anchor (incentives group; treatment group 2)
Number of subjects: 150
Study 36315224 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study 36315223 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36315227 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic iCBT
Number of subjects: 200
Study 36315227 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study 36315231 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepresence Robot (TR) intervention for 12 weeks
Number of subjects: 60
Study 36315231 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week follow-up after TR intervention
Number of subjects: 60
Study 36315347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographer-performed focused vascular ultrasound (FOVUS)
Number of subjects: 326
Study 36315347 — intervention group
Group type: COMPARATOR
Intervention: Emergency physician-performed FOVUS
Number of subjects: 326
Study 36315384 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 27996
Study 36315384 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 receptor agonists
Number of subjects: 27996
Study 36315498 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 0
Study 36315566 — intervention group
Group type: EXPERIMENTAL
Intervention: ENI group (19 patients)
Number of subjects: 358
Study 36315566 — intervention group
Group type: COMPARATOR
Intervention: Non ENI group (19 matched patients)
Number of subjects: 358
Study 36315607 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Troponin Fragmentation Assay
Number of subjects: 0
Study 36315921 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 2% circulating tumor cells (CTCs)
Number of subjects: 395
Study 36315921 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of CTCs by multiparameter flow cytometry
Number of subjects: 395
Study 36316061 — intervention group
Group type: EXPERIMENTAL
Intervention: INCAGN01949 monotherapy (7-1400 mg) in 14-day cycles
Number of subjects: 87
Study 36316072 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised follow-up survey after ED disposition
Number of subjects: 1682
Study 36316072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model for biphasic anaphylaxis (BA)
Number of subjects: 1682
Study 36316081 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care intervention developed in co-production with users
Number of subjects: 240
Study 36316081 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 240
Study 36316115 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervention
Number of subjects: 251
Study 36316115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 251
Study 36316315 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing 300 of their memory videos during a 3 T fMRI scan
Number of subjects: 23
Study 36316315 — intervention group
Group type: COMPARATOR
Intervention: Viewing 300 memory videos from another individual during a 3 T fMRI scan
Number of subjects: 23
Study 36316335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue purified inactivated vaccine (DPIV)
Number of subjects: 0
Study 36316438 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Surgical Margins (PSM)
Number of subjects: 2166
Study 36316438 — intervention group
Group type: COMPARATOR
Intervention: Negative Surgical Margins (NSM)
Number of subjects: 2166
Study 36316628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-citrulline (150 mg/kg)
Number of subjects: 10
Study 36316704 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS malaria with AKI
Number of subjects: 209
Study 36316704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpyrexia
Number of subjects: 209
Study 36316704 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 209
Study 36316733 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG value (≥ 92 mg/dl) following Italian Diabetes Societies recommendations for COVID 19 pandemic period
Number of subjects: 161
Study 36316733 — intervention group
Group type: EXPERIMENTAL
Intervention: IADPSG criteria
Number of subjects: 161
Study 36316733 — intervention group
Group type: COMPARATOR
Intervention: WHO'99 criteria
Number of subjects: 161
Study 36316788 — intervention group
Group type: EXPERIMENTAL
Intervention: New child diet quality index calculated from a 28-item dietary questionnaire
Number of subjects: 71
Study 36316788 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 24-hour diet recalls at the 13-month follow-up
Number of subjects: 71
Study 36316952 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-cancer early detection test
Number of subjects: 0
Study 36317012 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-mediator concentrate (PMC)
Number of subjects: 0
Study 36317056 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes self-management intervention with group education and race-congruent peer-based phone support.
Number of subjects: 17
Study 36317056 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes self-management intervention.
Number of subjects: 17
Study 36317254 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative peripheral nerve interfaces and intramuscular electrodes
Number of subjects: 0
Study 36317421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster T1 (n=708) - young, short asthma duration, low prevalence of CRSwNP
Number of subjects: 1263
Study 36317421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster T2 (n=263) - longest asthma duration
Number of subjects: 1263
Study 36317421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster T3 (n=292) - older, shortest asthma duration
Number of subjects: 1263
Study 36317421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster S1 (n=83) - mild-to-moderate asthma, normal lung function
Number of subjects: 1263
Study 36317421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster S2 (n=53) - severe asthma, longer asthma duration
Number of subjects: 1263
Study 36317421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster S3 (n=42) - severe asthma, late-onset
Number of subjects: 1263
Study 36317424 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment (measured using five-dimension EuroQol)
Number of subjects: 0
Study 36317424 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity (measured by the number of comorbidities)
Number of subjects: 0
Study 36317424 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight (BMI < 18.5)
Number of subjects: 14688
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight (BMI 18.5-24.9)
Number of subjects: 14688
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9)
Number of subjects: 14688
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI 30-34.9)
Number of subjects: 14688
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI ≥ 35)
Number of subjects: 14688
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 14688
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 14688
Study 36317512 — intervention group
Group type: EXPERIMENTAL
Intervention: TNM stages I, II, III
Number of subjects: 14688
Study 36317524 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese-enhanced magnetic resonance imaging
Number of subjects: 20
Study 36317524 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched volunteers)
Number of subjects: 20
Study 36317715 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and pembrolizumab
Number of subjects: 36
Study 36317867 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed Group
Number of subjects: 40
Study 36317867 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninstructed Group
Number of subjects: 40
Study 36317867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 36317927 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (9 IU·kg bw -1 epoetin β)
Number of subjects: 48
Study 36317927 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 48
Study 36317929 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for dispatching physicians in geriatric care
Number of subjects: 2671
Study 36317929 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with General Practitioner (GP) in the month preceding the call
Number of subjects: 2671
Study 36317959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean CHB-NAFLD patients
Number of subjects: 1226
Study 36317959 — intervention group
Group type: COMPARATOR
Intervention: Nonlean CHB-NAFLD patients
Number of subjects: 1226
Study 36318027 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 187
Study 36318030 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo single-voxel diffusion-weighted MR spectroscopy in participants with IS
Number of subjects: 0
Study 36318030 — intervention group
Group type: COMPARATOR
Intervention: In vivo single-voxel diffusion-weighted MR spectroscopy in healthy volunteers (HVs)
Number of subjects: 0
Study 36318233 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual PConnect program
Number of subjects: 136
Study 36318233 — intervention group
Group type: COMPARATOR
Intervention: In-person PConnect program
Number of subjects: 136
Study 36318307 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min passive stretching session at 80% of maximal DF angle
Number of subjects: 13
Study 36318387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly (qw)
Number of subjects: 2677
Study 36318387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 2677
Study 36318387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg (qw or q2w)
Number of subjects: 2677
Study 36318387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 2677
Study 36318494 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-5 Level 1 Cross-Cutting Symptom Measure (DSM-XC)
Number of subjects: 3533
Study 36318494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifactor solution of DSM-XC
Number of subjects: 3533
Study 36318705 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 181
Study 36318705 — intervention group
Group type: COMPARATOR
Intervention: Control (abiraterone or enzalutamide)
Number of subjects: 181
Study 36318879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose of 40 IU of vasopressin with epinephrine
Number of subjects: 148
Study 36318879 — intervention group
Group type: COMPARATOR
Intervention: Placebo with epinephrine
Number of subjects: 148
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-SYM
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: PAGI-SYM
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-QOL
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Straining
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fullness
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete bowel movements
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloating
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Distension
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain (upper)
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain (lower)
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloating (≥18 vs <18)
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower abdominal pain (≥18 vs <18)
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomach fullness (≥18 vs <18)
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal distension (≥18 vs <18)
Number of subjects: 402
Study 36319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment dissatisfaction (PAC-QOL)
Number of subjects: 402
Study 36319717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral administration of CV8102
Number of subjects: 0
Study 36319717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of i.t. CV8102 with systemic anti-PD-1 treatment
Number of subjects: 0
Study 36319790 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Orifice Specimen Excision (NOSE)
Number of subjects: 102
Study 36319877 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT-toolbox (open-access semi-automated segmentation tool)
Number of subjects: 10
Study 36319877 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentations
Number of subjects: 10
Study 36319896 — intervention group
Group type: EXPERIMENTAL
Intervention: CADISS® system
Number of subjects: 15
Study 36319944 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP/START-based in-hospital medication review
Number of subjects: 963
Study 36320022 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication for ADHD
Number of subjects: 40